GlaxoSmithKline, the British-based pharmaceuticals group, yesterday confirmed the disappointing performance of its male erectile dysfunction treatment Levitra with the sale back to Bayer of the marketing rights in most of the world outside the US.

Bayer, the German group, said it had paid €208m ($272m) to buy out GSK as joint promoter of the treatment in Europe, Asia, the Pacific, Latin America and Canada.